Armistice Capital’s BioXcel Therapeutics BTAI Stock Holding History

Armistice Capital’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,910,076	Closed	-$2.56M	–	345
2026 Q1	$2.56M	Buy	+1,910,076	New	+$3.15M	0.05%	151
2025 Q1	–	Sell	-269,688	Closed	-$1.61M	–	236
2024 Q4	$1.61M	Buy	+269,688	New	+$2.25M	0.02%	160
2024 Q3	–	Sell	-186,688	Closed	-$3.82M	–	268
2024 Q2	$3.82M	Buy	186,688 +163,502	+705%	+$5.47M	0.05%	126
2024 Q1	$1.05M	Buy	+23,186	New	+$1.11M	0.01%	161

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital's BTAI Position: Q2 2026 in Review

Armistice Capital sold out of BioXcel Therapeutics (BTAI) in Q2 2026, closing a stake of 1,910,076 shares — an estimated $2.56M sold.

Armistice Capital first reported a position in BTAI in Q1 2024 and held it in 4 quarters. The position peaked at $3.82M in Q2 2024. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

Armistice Capital reported no remaining BioXcel Therapeutics position as of Q2 2026 after selling out during the quarter.
Armistice Capital sold 1,910,076 BioXcel Therapeutics shares in Q2 2026, an estimated $2.56M.
Armistice Capital first reported a position in BioXcel Therapeutics in Q1 2024 and held it in 4 quarters.
Armistice Capital's BioXcel Therapeutics position peaked at $3.82M in Q2 2024.
47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.